Day One Biopharma Q1 net loss $62.4M, launches OJEMDA after April FDA approval

Day One Biopharmaceuticals, Inc.

2024-Q1 EPS reported -$0.72

Q1 2024 net loss $62.4M vs $42.4M YoY; cash $317.9M expected to fund ops into 2026.
OJEMDA (tovorafenib) received FDA accelerated approval in April for relapsed/refractory BRAF-altered pLGG; first prescriptions written.
R&D expenses $40.2M (up from $27.8M) driven by compensation, PRV buyback, and clinical activities.
Phase 3 FIREFLY-2 front-line pLGG trial enrolling with >90 sites activated globally.
Rare pediatric disease priority review voucher received upon OJEMDA approval.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Day One Biopharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income $62.4 million.

Period: the quarter ended March 31, 2024
Net income: $62.4 million
Result: reported results

Exact text from the filing

Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-053598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.